- | MindMed
A CMO’s Perspective on Designing Clinical Trials for a Psychedelic-Derived Drug Candidate
From a trial design perspective, we’ve tried to make these trials as familiar to stakeholders – regulators, prescribers, payors – as possible. What’s remarkable here are the qualities of the drug that we’re developing, MM120, a pharmaceutical formulation of LSD; we don’t need to do anything inconsistent with the history of psychiatric clinical trials beyond that.
- | Pharvaris
Data show sustained benefits of deucrictibant for HAE attacks
Pharvaris is moving forward with Phase 3 clinical trials. The RAPIDe-3 study (NCT06343779) is testing an immediate-release formulation of deucrictibant, called PHVS416, as an on-demand therapy for HAE. Recruitment is ongoing at sites in the U.S., Puerto Rico, South Korea, and Germany.
- | Revolo Biotherapeutics
’1104: tackling the root cause of allergic disease
Revolo Biotherapeutics’ CEO, Woody Bryan, discusses how ‘1104, the Company’s lead candidate for allergic diseases, shifts the immune system from a pro-inflammatory state to a homeostatic state, offering potential remission for allergic conditions.
- | Recce Pharmaceuticals
Recce Pharmaceuticals Advances Antibiotic Development to Combat Antimicrobial Resistance
At the World AMR Congress, Recce Pharmaceuticals contributes by making strides with a synthetic compound designed to target bacterial mutations, underscoring the need for innovation in addressing antimicrobial resistance (AMR). “Our compound is entirely synthetic,” Graham said. “We started with first principles, designing a compound that remains effective with repeated use.”
- | Araris Biotech
Combatting disease with antibody drug conjugates
This conversation features Dr Philipp Spycher, CSO and co-founder at Araris Biotech, and Dr Rebecca Boohaker, Director of Oncology at Southern Research.
- | MindMed
Midtown biotech sells $75M to the public to show FDA the promise of psychedelics
Biotech company MindMed is shoring up its cash stockpile to inch its psychedelic therapies towards approval after the feds’ recent thumbs-down of using MDMA to treat post-traumatic stress disorder.
- | Spinogenix
World-first MND drug trial offers hope to those living with the disorder
Spinogenix founder Dr Stella Sarraf joined Sky News Business Editor Ross Greenwood to discuss the ongoing groundbreaking trial.
- | Lumos Pharma
Phase 2 Trial Evaluating LUM-201 for Treatment of Growth Hormone Deficiency
Pisit “Duke” Pitukcheewanont, MD, Chief Medical Officer for Lumos Pharma, discusses a phase 2 trial evaluating LUM-201 (ibutamoren) for treatment of growth hormone deficiency.